Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Rx-360 Consortium Aims To Curb Supply Chain Threats

This article was originally published in The Tan Sheet

Executive Summary

Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008

You may also be interested in...



Rx-360 Issues Guide On Remote Supplier Audits; CEO Warns They May Take Longer At First

Manufacturers should expect that remote audits of suppliers may take longer than onsite ones until they get more familiar with these audits; it is also important to abide by data confidentiality rules and take frequent breaks when conducting these audits, says Rx-360 CEO.

FDA Seeks Public Input On Secrets Of Profit-Motivated Adulteration

FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products

FDA Strengthens Inspections Of Chinese Drug Firms In Heparin Aftermath

BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S

Topics

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel